The GLP-1 therapies available in Australia and how theyre accessed There are currently two classes of GLP-1 based therapies approved in Australia glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as Ozempic, Trulicity, Victoza, and Wegovy, and dual glucose-dependent insulinotropic polypeptide receptor agonists ((GIP)/GLP-1 RAs), such as Mounjaro
Liver Fat & MASLD: A Phase 2a trial published in Nature Medicine demonstrated significant liver fat reduction and improved insulin sensitivity in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), through a direct hepatic mechanism unique to Retatrutide
Looking at the positives, a large trial of over 17,600 adults found that Wegovy reduced the rate of cardiovascular events, including heart disease and stroke, by 20%
H.FawzyM
Most patients notice appetite reduction between days 714 after their first injection
Dehydration is one of the leading contributors to dizziness for those taking GLP-1 medications